KRAS and non-small cell lung carcinoma: The meta-analysis conducted by Fengzhi Zhao et al., which included a total of 6950 patients, showed that the prevalence of ALK translocations was 6.8 % in NSCLC patients; this study did not select for ethnicity, but once again demonstrated that ALK translocations are practically mutually exclusive with EGFR and KRAS mutations [49].